SCHEMBL4194876

SCHEMBL4194876

CC1CCC1(C)C(N)=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL28293251 0.98 TDP1 (0.34)
SCHEMBL7374383 0.86 PDK1 (0.35)
SCHEMBL3347705 0.85 EPHX1 (0.38)
Hydrochloric Acid SCHEMBL7367915 0.85 PDK1 (0.34)
Hydrochloric Acid SCHEMBL390395 0.83 EPHX1 (0.36)
SCHEMBL10592690 0.80 TDP1 (0.33)
SCHEMBL3152534 0.78
SCHEMBL3152529 0.78
SCHEMBL5314812 0.77
SCHEMBL28437217 0.77

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240150377-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS INCORPORATED 2024-05-09 US disclosed
CN-110392678-B Compounds and methods for IDO and TDO modulation, and indications therefor 普莱希科公司 2023-10-20 CN disclosed
CN-116601158-A Modulators of cystic fibrosis transmembrane conductance regulator 弗特克斯药品有限公司 2023-08-15 CN disclosed
CN-116370448-A Modulators of SESTRIN-GATOR2 interactions and uses thereof 纳维托制药有限公司 2023-07-04 CN disclosed
CN-110809467-B Modulators of SESTRIN-GATOR2 interactions and uses thereof 纳维托制药有限公司 2023-03-10 CN disclosed
CN-113226462-A Heteroaromatic compounds as VANIN inhibitors 勃林格殷格翰国际公司 2021-08-06 CN disclosed
EP-3814338-A1 PROTEASOME ACTIVITY ENHANCING COMPOUNDS Proteostasis Therapeutics, Inc. (US) 2021-05-05 EP disclosed
US-10912750-B2 Modulators of Sestrin-GATOR2 interaction and uses thereof NAVITOR PHARMACEUTICALS, INC. (US) 2021-02-09 US disclosed
CN-112119072-A Compounds and methods for IDO and TDO modulation, and indications thereof 普莱希科公司 2020-12-22 CN disclosed
EP-3615019-A1 MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF Navitor Pharmaceuticals, Inc. (US) 2020-03-04 EP disclosed
US-20160005595-A1 Photoresist and Method of Manufacture TAIWAN SEMICONDUCTOR MANUFACTURING COMPANY, LTD. (TW) 2016-01-07 US disclosed
US-20150111384-A1 Anti-Reflective Layer and Method TAIWAN SEMICONDUCTOR MANUFACTURING COMPANY (TW) 2015-04-23 US disclosed
US-20140273457-A1 Anti-Reflective Layer and Method TAIWAN SEMICONDUCTOR MANUFACTURING COMPANY, LTD. (TW) 2014-09-18 US disclosed
CN-101506736-B Composition containing liquid additive for forming resist underlayer film, underlayer film forming method and semiconductor device manufacture method NISSAN CHEMICAL IND LTD 2013-07-10 CN disclosed
US-8481247-B2 Resist underlayer film forming composition containing liquid additive NISSAN CHEMICAL INDUSTRIES, LTD. 2013-07-09 US disclosed
CN-101076519-B Amide compound and thrombopoietin receptor activator NISSAN CHEMICAL IND LTD 2011-07-20 CN disclosed
US-20090311624-A1 RESIST UNDERLAYER FILM FORMING COMPOSITION CONTAINING LIQUID ADDITIVE NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2009-12-17 US disclosed
CN-101506736-A Resist underlayer film forming composition containing liquid additive NISSAN CHEMICAL IND LTD (JP) 2009-08-12 CN disclosed
EP-1951660-A1 HISTAMINE-3 RECEPTOR ANTAGONISTS Pfizer Products Incorporated (US) 2008-08-06 EP disclosed
WO-2007049123-A1 HISTAMINE-3 RECEPTOR ANTAGONISTS PFIZER PRODUCTS INC. (US) 2007-05-03 WO disclosed